In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
-- In a real-world, observational, retrospective study of FYCOMPA as a first add-on therapy, 61% (19/31) of patients with generalized seizures achieved seizure freedom, with an overall retention rate of 85% (127/149) at 12 months
- Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)